On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications

Abstract There is increasing interest in the therapeutic targeting of proteases for the treatment of important diseases. Additionally new protein-based therapeutic strategies have the potential to widen the available treatments against these pathologies. In the last decade, accumulated evidence has confirmed that the family of proteases known as proprotein convertases (PCs) are potential targets for viral infections, osteoarthritis, cancer and cardiovascular disease, among others. Nevertheless, there are still many unanswered questions about the relevance of targeting PCs in a therapeutic context, especially regarding the anticipated secondary effects of treatment, considering the observed embryonic lethality of some PC knockout mice. In this review, the benefits of PCs as pharmacological targets will be discussed, with focus on concepts and strategies, as well as on the state of advancement of actual and future inhibitors.

[1]  N. Seidah,et al.  The isoforms of proprotein convertase PC5 are sorted to different subcellular compartments , 1996, The Journal of cell biology.

[2]  G. Salvesen,et al.  Emerging principles in protease-based drug discovery , 2010, Nature Reviews Drug Discovery.

[3]  Nikolaj Blom,et al.  Prediction of proprotein convertase cleavage sites. , 2004, Protein engineering, design & selection : PEDS.

[4]  D. Griggs,et al.  Proprotein convertase activation of aggrecanases in cartilage in situ. , 2008, Archives of biochemistry and biophysics.

[5]  C. Van Noorden,et al.  Antiprotease therapy in cancer: hot or not? , 2006, Expert opinion on biological therapy.

[6]  T. Watanabe,et al.  Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. , 1991, The Journal of biological chemistry.

[7]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[8]  Jianhua Wu,et al.  FurinDB: A Database of 20-Residue Furin Cleavage Site Motifs, Substrates and Their Associated Drugs , 2011, International journal of molecular sciences.

[9]  A. Prat,et al.  The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2* , 2008, Journal of Biological Chemistry.

[10]  H. Ma,et al.  Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis , 2005, Nature.

[11]  A. Godwin,et al.  Increased Expression of the Pro-Protein Convertase Furin Predicts Decreased Survival in Ovarian Cancer , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[12]  C. Boileau,et al.  Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents , 2010, Expert opinion on therapeutic patents.

[13]  Jeffrey W. Smith,et al.  Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens* , 2007, Journal of Biological Chemistry.

[14]  Piotr Cieplak,et al.  Substrate Cleavage Analysis of Furin and Related Proprotein Convertases , 2008, Journal of Biological Chemistry.

[15]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[16]  N. Seidah,et al.  Inhibition of Chikungunya Virus Infection in Cultured Human Muscle Cells by Furin Inhibitors , 2008, Journal of Biological Chemistry.

[17]  Y. Maeda,et al.  The acidic environment of the Golgi is critical for glycosylation and transport. , 2010, Methods in enzymology.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  A. Prat,et al.  The proprotein convertases and their implication in sterol and/or lipid metabolism , 2006, Biological chemistry.

[20]  I. Lindberg,et al.  Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. , 2010, Journal of medicinal chemistry.

[21]  D. Lowy,et al.  Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Prat,et al.  The proprotein convertases are potential targets in the treatment of dyslipidemia , 2007, Journal of Molecular Medicine.

[23]  B. Ross,et al.  Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. , 2007, Analytical biochemistry.

[24]  N. Seidah,et al.  The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis , 2010, Current atherosclerosis reports.

[25]  R. Day,et al.  Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition , 2005, Trends in Pharmacological Sciences.

[26]  P. Espenshade,et al.  Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. , 1998, Molecular cell.

[27]  T. Komiyama,et al.  Furin Inhibition by Compounds of Copper and Zinc* , 2004, Journal of Biological Chemistry.

[28]  J. A. Hobden,et al.  Nona-D-Arginine Amide for Prophylaxis and Treatment of Experimental Pseudomonas aeruginosa Keratitis , 2010, Current eye research.

[29]  Benoît Cadieux,et al.  Molecular cloning and embryonic expression of zebrafish PCSK5 co‐orthologues: Functional assessment during lateral line development , 2010, Developmental dynamics : an official publication of the American Association of Anatomists.

[30]  N. Seidah,et al.  Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. , 2008, Virology.

[31]  C. Brenner,et al.  The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. , 1993, The Biochemical journal.

[32]  A. Strongin,et al.  Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. , 2010, The international journal of biochemistry & cell biology.

[33]  B. Hay,et al.  Aminopyrrolidineamide inhibitors of site-1 protease. , 2007, Bioorganic & medicinal chemistry letters.

[34]  N. Seidah,et al.  Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. , 1996, The Biochemical journal.

[35]  S. Millis,et al.  Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine , 2006, Proceedings of the National Academy of Sciences.

[36]  R. Day,et al.  Inhibitors of the subtilase-like pro-protein convertases (SPCs). , 2002, Current pharmaceutical design.

[37]  N. Seidah,et al.  Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides 1 Published on the World Wide Web on 17 August 1999. 1 , 1999, Brain Research.

[38]  N. Seidah,et al.  The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A , 2006, Journal of Biological Chemistry.

[39]  I. Fournier,et al.  Molecular Validation of PACE4 as a Target in Prostate Cancer. , 2011, Translational oncology.

[40]  I. Wang,et al.  Pharmacologic Inhibition of Site 1 Protease Activity Inhibits Sterol Regulatory Element-Binding Protein Processing and Reduces Lipogenic Enzyme Gene Expression and Lipid Synthesis in Cultured Cells and Experimental Animals , 2008, Journal of Pharmacology and Experimental Therapeutics.

[41]  A. Grodzinsky,et al.  Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. , 2010, Archives of biochemistry and biophysics.

[42]  A. Roebroek,et al.  Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3 Cloning and primary sequence of a 5 kb cDNA , 1992, FEBS letters.

[43]  D. Szymkowski Rational optimization of proteins as drugs: a new era of 'medicinal biology'. , 2004, Drug discovery today.

[44]  R. B. Rawson Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). , 2003, Biochemical Society symposium.

[45]  M. Nachtigal,et al.  Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. , 2003, Molecular cancer research : MCR.

[46]  A. Klein-Szanto,et al.  Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. , 2002, Carcinogenesis.

[47]  S. O’Rahilly,et al.  Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene , 1997, Nature Genetics.

[48]  F. Pinet,et al.  Expression of PC2 and PC1/PC3 in human pheochromocytomas , 1994, Molecular and Cellular Endocrinology.

[49]  K. Soppimath,et al.  Novel delivery technologies for protein and peptide therapeutics. , 2006, Current pharmaceutical biotechnology.

[50]  R. Day,et al.  Proteolytic Processing of Angiopoietin-like Protein 4 by Proprotein Convertases Modulates Its Inhibitory Effects on Lipoprotein Lipase Activity* , 2011, The Journal of Biological Chemistry.

[51]  A. Lauwers,et al.  Limited Redundancy of the Proprotein Convertase Furin in Mouse Liver* , 2004, Journal of Biological Chemistry.

[52]  G. Kundu,et al.  p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. , 2010, Cancer research.

[53]  N. Seidah,et al.  Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters. , 1999, The Biochemical journal.

[54]  G. Thomas,et al.  alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Wu Jianhua,et al.  Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors , 2010, International journal of biological sciences.

[56]  A. Basak,et al.  A Novel Enediynyl Peptide Inhibitor of Furin That Blocks Processing of proPDGF-A, B and proVEGF-C , 2009, PloS one.

[57]  Yan Wang,et al.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates , 2009, Proceedings of the National Academy of Sciences.

[58]  D. Constam,et al.  Imaging proprotein convertase activities and their regulation in the implanting mouse blastocyst , 2010, The Journal of cell biology.

[59]  I. Lindberg,et al.  Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. , 2005, Journal of molecular biology.

[60]  J. Lieberman,et al.  The silent treatment: siRNAs as small molecule drugs , 2006, Gene Therapy.

[61]  J. Deisenhofer,et al.  Molecular basis for LDL receptor recognition by PCSK9 , 2008, Proceedings of the National Academy of Sciences.

[62]  C. Dubois,et al.  Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans‐golgi network to the cell surface , 2012, Journal of cellular physiology.

[63]  Mansoor M Ahmed,et al.  The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. , 2006, Current molecular medicine.

[64]  Bonnie Peng,et al.  The role of prohormone convertase‐2 in hypothalamic neuropeptide processing: a quantitative neuropeptidomic study , 2006, Journal of neurochemistry.

[65]  C. Stevenson Advances in peptide pharmaceuticals. , 2009, Current pharmaceutical biotechnology.

[66]  I. Lindberg,et al.  Polyarginines Are Potent Furin Inhibitors* , 2000, The Journal of Biological Chemistry.

[67]  R. Leduc,et al.  Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. , 2000, Journal of molecular endocrinology.

[68]  N. Seidah,et al.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. , 2002, The American journal of pathology.

[69]  D. Rader,et al.  Angiopoietin-like Protein 3 Inhibits Lipoprotein Lipase Activity through Enhancing Its Cleavage by Proprotein Convertases* , 2010, The Journal of Biological Chemistry.

[70]  B. Scheithauer,et al.  Distribution and Regulation of Proconvertases PC1 and PC2 in Human Pituitary Adenomas , 1999, Pituitary.

[71]  N. Seidah,et al.  Proprotein convertases: lessons from knockouts , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  H. Klenk,et al.  Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gpl60 , 1992, Nature.

[73]  H. de Haard,et al.  Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.

[74]  Michele Bernasconi,et al.  Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model , 2010, PloS one.

[75]  I. Lindberg,et al.  Synthetic Small-Molecule Prohormone Convertase 2 Inhibitors , 2009, Molecular Pharmacology.

[76]  J. A. Hobden,et al.  Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis. , 2009, Investigative ophthalmology & visual science.

[77]  U. Reimer,et al.  Translating peptides into small molecules. , 2006, Molecular bioSystems.

[78]  A. Roebroek,et al.  MMTV-cre-mediated fur inactivation concomitant with PLAG1 proto-oncogene activation delays salivary gland tumorigenesis in mice. , 2008, International journal of oncology.

[79]  A. Prat,et al.  Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation , 2009, The Journal of Biological Chemistry.

[80]  R. Schneiderman,et al.  Some biochemical and biophysical parameters for the study of the pathogenesis of osteoarthritis: a comparison between the processes of ageing and degeneration in human hip cartilage. , 1989, Connective tissue research.

[81]  Xiaorong Zhu,et al.  Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics , 2010, Journal of neurochemistry.

[82]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[83]  W. V. D. Van de Ven,et al.  Curbing activation: proprotein convertases in homeostasis and pathology , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  R. Day,et al.  Furin Processing and Proteolytic Activation of Semliki Forest Virus , 2003, Journal of Virology.

[85]  Alnawaz Rehemtulla,et al.  Inhibition of Furin/Proprotein Convertase-catalyzed Surface and Intracellular Processing by Small Molecules* , 2009, The Journal of Biological Chemistry.

[86]  A. Klein-Szanto,et al.  PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. , 2005, Cancer research.

[87]  A. Klein-Szanto,et al.  Elevated furin expression in aggressive human head and neck tumors and tumor cell lines , 2001, Molecular carcinogenesis.

[88]  S. Kunz,et al.  Antiviral Activity of a Small-Molecule Inhibitor of Arenavirus Glycoprotein Processing by the Cellular Site 1 Protease , 2010, Journal of Virology.

[89]  Dongqing Wei,et al.  Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin , 2008, Amino Acids.

[90]  M Chrétien,et al.  Pro‐protein convertase gene expression in human breast cancer , 1997, International journal of cancer.

[91]  R Beuscart,et al.  Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. , 1990, Cancer research.

[92]  N. Seidah,et al.  Proprotein convertases as therapeutic targets , 2008 .

[93]  H. Klenk,et al.  Cleavage Activation of the Influenza Virus Hemagglutinin and Its Role in Pathogenesis , 2008 .

[94]  M. O’Kennedy,et al.  Biolistic mediated sorghum (Sorghum bicolor L. Moench) transformation via mannose and bialaphos based selection systems , 2010 .

[95]  A. Prat,et al.  Deletion of the Gene Encoding Proprotein Convertase 5/6 Causes Early Embryonic Lethality in the Mouse , 2006, Molecular and Cellular Biology.

[96]  I. Lindberg,et al.  The Furin Inhibitor Hexa-d-Arginine Blocks the Activation of Pseudomonas aeruginosa Exotoxin A In Vivo , 2002, Infection and Immunity.

[97]  R. Leduc,et al.  Inhibitory Potency and Specificity of Subtilase-like Pro-protein Convertase (SPC) Prodomains* , 2002, The Journal of Biological Chemistry.

[98]  Philip Smith,et al.  The localization of the insulin‐like growth factor receptor 1 (IGFR‐1) in benign and malignant breast tissue , 1997, The Journal of pathology.

[99]  N. Seidah,et al.  Protease inhibitors suppress in vitro growth of human small cell lung cancer , 1993, Peptides.

[100]  E. Fleck,et al.  Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. , 2004, Biochemical and biophysical research communications.

[101]  A. Beck‐Sickinger,et al.  Peptide drugs to target G protein-coupled receptors. , 2010, Trends in pharmacological sciences.

[102]  A. Klein-Szanto,et al.  Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. , 2010, Neoplasia.

[103]  J. Creemers,et al.  Knock-out mouse models of proprotein convertases: unique functions or redundancy? , 2008, Frontiers in bioscience : a journal and virtual library.

[104]  N. Seidah,et al.  Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. , 2008, The Journal of clinical investigation.

[105]  N. Seidah What lies ahead for the proprotein convertases? , 2011, Annals of the New York Academy of Sciences.

[106]  Annik Prat,et al.  The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model , 2009, Molecular Cancer.

[107]  N. Seidah,et al.  The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. , 2005, Molecular biology of the cell.

[108]  Vivian Hook,et al.  Unique biological function of cathepsin L in secretory vesicles for biosynthesis of neuropeptides , 2010, Neuropeptides.

[109]  S. Kunz,et al.  Targeting the Proteolytic Processing of the Viral Glycoprotein Precursor Is a Promising Novel Antiviral Strategy against Arenaviruses , 2009, Journal of Virology.

[110]  I. Lindberg,et al.  Short Polybasic Peptide Sequences Are Potent Inhibitors of PC5/6 and PC7: Use of Positional Scanning-Synthetic Peptide Combinatorial Libraries as a Tool for the Optimization of Inhibitory Sequences , 2007, Molecular Pharmacology.

[111]  E. Fleck,et al.  Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels , 2005, Journal of Molecular Medicine.

[112]  R. Ala-aho,et al.  Matrix metalloproteinases as therapeutic targets in cancer. , 2005, Current cancer drug targets.